Interim Safety Results in Two Phase 1/2 Open-label, Dose-escalation Clinical Trials of Subretinal Gene Therapy with AGTC-401 (rAAV2tYF-PR1.7-hCNGB3) and AGTC-402 (rAAV2tYF-PR1.7-hCNGA3) in Subjects with Achromatopsia (ACHM)

AGTC-402 - AGTC

https://arvo2022.arvo.org/meetings/yJoXZKSvHkgDBGraL

Alessandro Iannaccone; Mark Pennesi; Paul Yang; Andreas Lauer; Robert Sisk; Ninel Gregori; Janet Davis; Byron Lam; Christine Kay; Mauro Goldbaum; Bright Ashimatey; Feng Zhu; Matthew Feinsod; Lejla Vajzovic

Apr 29, 2022